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The following review has been prepared in collaboration with members of the MRC-NIHR Trials 
Methodology Research Partnership ​1​. The reviewers named above, and other, unnamed 
discussants of the paper, are all qualified statisticians with experience in clinical trials. Our 
objective is to provide a rapid review of publications, preprints and protocols from clinical trials of 
COVID-19 treatments, independent of journal specific review processes. We aim to provide 
timely, constructive, focused, clear advice aimed at improving both the research outputs under 
review, as well as future studies. Given our collective expertise (clinical trial statistics) our 
reviews focus on the designs of the trials and other statistical content (methods, presentation 
and accuracy of results, inferences). This review reflects the expert opinions of the named 
authors, and does not imply endorsement by the MRC-NIHR Trials Methodology Research 
Partnership, its wider membership, or any other organization.  
 
Here we review ​Hydroxychloroquine in patients with COVID-19: an open-label, randomized, 
controlled trial​, by Tang ​et al​. A preprint of the trial was posted to medrxiv.org on April 14th 
(​https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1​).  
 
Our review, detailed below, identified issues with how the decision was made to stop the 
trial early, the randomization and allocation concealment procedures, and the methods 
for estimating subgroup specific effects. We also felt that the authors overstated the case 
for efficacy. Due to these issues, we recommend that it would be more appropriate to 
interpret the study as an inconclusive finding.  
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License ​2​.  
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Study Summary 
 
The paper reports a two-arm parallel randomized controlled trial planned in 360 patients 
hospitalized with rt-PCT confirmed COVID-19. The study was conducted in 16 Chinese 
COVID-19 treatment centers in February, 2020. Patients were randomized using a 1:1 
allocation ratio to receive either standard-of-care, or standard-of-care plus hydroxychloroquine 
(1200 mg daily for three days, then 800 mg daily for up to 2 weeks in patients with 
mild/moderate illness, or up to 3 weeks in patients with severe illness). The primary outcome 
was the time to a negative SARS-CoV-2 rt-PCR, up to 28 days post-randomization. Secondary 
outcomes included the time to improvement of clinical symptoms (normalization of fever, SpO2, 
and respiratory symptoms), time to normalization of elevated CRP, and time to recovery of 
lymphopenia, all up to 28 days post-randomization.  
 
According to the paper, there was a planned interim analysis once 150 patients were treated for 
at least 7 days. At this point, based on the results we present below, the decision was made to 
stop the trial. In the intention-to-treat analysis (n = 75 in each arm), the hazard ratio (HR) for 
time to a negative rt-PCR was 0.85 (95%CI 0.58 to 1.23) favoring the hydroxychloroquine arm. 
The HR for time to resolution of symptoms was 1.01 (0.59 to 1.74; n = 119), though in a 
subgroup of these patients who weren’t prescribed any other anti-SARS-CoV-2 medicines 
during the trial (n = 28), the HR for time to resolution of symptoms was 8.8 (1.1 to 71.2) favoring 
the hydroxychloroquine arm.  The HR for time to normalization of elevated CRP was 1.31 (0.64 
to 2.71; n = 48) and the HR for recovery of lymphopenia was 1.16 (0.44 to 3.04; n = 38), both 
favoring the hydroxychloroquine arm. Finally, the reduction of CRP from baseline to day 28 was 
greater in the hydroxychloroquine arm (difference in means of 4.27, p = 0.045, n = 137).  
 
Based on these findings, the authors concluded that administration of hydroxychloroquine led to 
greater alleviation of clinical symptoms, possibly “through anti-inflammatory properties” and 
clinicians should consider its use in “symptomatic patients with elevated CRP...particularly in 
patients at higher risk.” 
 
We sincerely thank the authors for their contribution to our collective understanding of 
COVID-19, for their commitment to the timely dissemination of research results. 
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Major comments 
 
The methodological basis for stopping early was unsound.  
 
As noted in the summary above, the reported analysis was of data from 150 patients, while the 
study planned to recruit 360. The authors reported that this was a planned interim analysis and 
that they would employ an alpha-spending approach to maintain strict type 1 error control. 
When applied properly, an alpha-spending approach means that earlier looks are “penalized” in 
that you would require a smaller p-value than your nominal type 1 error rate (e.g. 0.05) to 
declare a “statistically significant” result. However, there is no evidence of using this approach in 
the reported analysis - all of the results are interpreted in light of their nominal p-values, with no 
such penalty. Further, there was no detail provided on how the data safety and monitoring board 
(DSMB) considered this information when they concluded there was “good efficacy of HCQ in 
symptom alleviation and anti-inflammation reported from the interim analysis”.  
Interestingly, the discussion seems to imply that the early stopping was at least partly driven to 
the decline in cases in mid March. If the decision to stop early was in fact due to poor 
enrollment, with no consideration of the interim results, then our concerns about early stopping 
are somewhat alleviated, as it is a very different situation compared to having the ​option ​to stop 
or continue. However, it is still confusing to say you are using a methodologically sound 
approach to early stopping, and then completely ignore it when analysing and interpreting the 
study data.  
Recommendations​:  
For future studies 
● It is often a good idea to consider including a methodologically sound method for early 
stopping for treatment futility and/or efficacy, though investigators often don’t. There are 
multiple approaches available under both frequentist and Bayesian frameworks for 
statistical inference. However, once the decision has been made to use such an 
approach, you need to follow through on the analysis and interpretation.  
For the reader 
● Lack of clarity around the reasons for stopping early, and failure to implement their 
planned approach to the interim analysis, mean that the results should be interpreted 
cautiously.  
 
 
The interpretation of subgroups was done incorrectly.  
 
It is common to estimate treatment effects in patient subgroups. Generally, the appropriate way 
to do this is to use a multivariable model that includes a treatment-by-subgroup interaction term. 
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The authors unfortunately did not describe exactly how they estimated their reported subgroup 
estimates, and only reported the 95% CIs of these effects within subgroups. This matters 
because a large estimated effect on a secondary outcome in one subgroup seemingly played an 
important role in their conclusion that hydroxychloroquine was efficacious (HR 8.8 [95%CI 1.1 to 
71.2] for time to resolution of symptoms in 28 patients who weren’t prescribed any other 
anti-SARS-CoV-2 medicines during the trial). This conclusion is apparently based on the 
observation that the subgroup specific CI didn’t include the null HR of 1, without consideration of 
the interaction term that would more directly indicate whether the effect in this group is different 
than that in its complement (patients who ​did ​receive another nti-SARS-CoV-2 medicines during 
the trial).  
 
Finally, the evaluation of so many subgroups raises concerns about multiplicity. As the number 
of subgroups tested increases, so does the probability of seeing a “significant” result by chance. 
Thus basing the conclusion of the trial on a single such subgroup result (out of many tested 
subgroup effects) is problematic.  
 
For future studies 
● If you are interested in estimating subgroups-specific treatment effects, the subgroups 
should be pre-registered in the protocol’s statistical analysis plan; then tested using the 
appropriate treatment by subgroup interaction term; and cautiously interpreted in a 
manner that considers multiplicity.  
For this study 
● Report interaction terms from multivariable models that test for subgroup specific 
treatment effects, and interpret the results in light of any resulting multiplicity.  
For the reader 
● Lack of clarity around how subgroup effects were estimated, incorrect statsitical 
inference based on subgroup specific CIs, and testing many subgroups with no 
consideration of multiplicity, should warrant increased caution when interpretating the 
results.  
 
 
Important details regarding the randomization and allocation 
concealment were unclear or missing.  
 
The randomisation was 1:1 and apparently stratified by mild/moderate or severe COVID19. 
However, there was no mention of blocking or any other means of restricting the randomization 
within strata, and the analyses of the data did not adjust for the stratification; and without 
blocking, it would be unusual to land exactly on a 75:75 allocation by chance alone (about 6%). 
It is also not clear if there was stratification by centre (which would be typical in a multi-centre 
trial), and there are no details on how the allocations were distributed to centres or how 
allocation concealment was maintained. This is particularly concerning for an unblinded study.  
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For future studies 
● Please refer to CONSORT ​3​ when designing and reporting your trial. There is excellent 
guidance there on randomization and allocation concealment procedures.  
For this study 
● Clarify the reporting of the randomization and allocation concealment, following 
CONSORT.  
For the reader 
● The lack of clarity around randomization and allocation concealment warrant increased 
caution when interpreting the results.  
 
The overall conclusions are questionable.  
 
While the authors acknowledged there was no apparent difference in study arms on the primary 
outcome, a negative rt-PCR by day-28 post-randomization, they concluded that doctors should  
consider its use in “symptomatic patients with elevated CRP … particularly in patients at higher 
risk”  due to greater alleviation of clinical symptoms, possibly “through anti-inflammatory 
properties”. However, this is based on a questionable subgroup effect for symptom alleviation 
(described above) but no apparent alleviation of symptoms in the entire sample, and a greater 
reduction of CRP (which was not an outcome listed in the trial registry) in the 
hydroxychloroquine arm. Further, even when the data hinted that hydroxychloroquine might lead 
to beneficial outcomes more quickly, it didn’t translate to differences in these outcomes at the 
end of the study period. Thus even without the issues described earlier in the review (and other 
minor points raised below), we suspect most experts would view this as a null or inconclusive 
finding.  
 
For the reader 
● This study should be interpreted as a null or inconclusive result, not as evidence for the 
efficacy of hydroxychloroquine.  
 
Minor points 
- The subgroup analysis that played such an important role in the authors’ interpretation of the 
study data was based on a post-randomization factor that could have been influenced by 
treatment and prognosis. This is especially problematic since the trial was not blinded.  
 
- They reported that the interim analysis took place when they had 150 patients completing at 
least 7 days of treatment, but it isn’t clear how many of those patients completed their treatment 
regimen, or how many were followed up the full 28 days post-randomization (there were no 
deaths).  
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- It’s unclear how “symptom alleviation” was calculated. Did participants have to meet all three 
criteria (normalization of fever, SpO2, and respiratory symptoms)? Further, it’s not possible to 
tell how the individual criteria were assessed, which is important since the trial was unblinded 
and the subjectivity of this outcome is clearly important as it contributed to the authors’ 
conclusion that hydroxychloroquine was efficacious.  
 
- Adjustment for prognostic covariates using multivariable models would have likely improved 
the precision of effect estimates. Similarly, CRP and blood lymphocytes were analysed as 
changes from baseline, whereas a baseline-adjusted model would have been a more efficient 
use of the data.  
 
- The overall description of methods and presentation of results were chaotic and confusing. 
Some examples include: 
 
The % of events in figure 2 (70.7% vs74.7%) differs from the text (85.4% vs 81.3%). The 
same happens for symptom alleviation figures reported in the text and in figure 3.  
 
There was inconsistency between outcome designations in the text and figures. For 
example, figure 3 reads “cumulative improvement rate”, but in the results section the 
outcome is called “symptom alleviation”.  
 
The analysis sets vary across outcomes, with no clear explanation of why. Authors 
described their analysis as “intention-to-treat”, but this seems to be the case for the 
primary outcome only. Other outcomes, such as improvement, exclude asymptomatic 
participants, and the analysis of normalization of elevated CRP excludes those with 
normal CRP.  
 
Outcomes mentioned in the methods were not reported in the results.  
 
 
Open Data 
No.  
 
Anonymized datasets can be made available on reasonable request after approval from the trial 
management committee and after signing a data access agreement. Proposals should be 
directed to the corresponding author.  
Open Analysis Code 
No.  
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Pre-registered study design 
No.  
PubPeer 
There may be comments on the PubPeer page for the published version of this paper. 
https://pubpeer.com/publications/C4637CE5485BC9935137B01EDC87E6 
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CONSORT CHECKLIST 
To support the review, we completed the CONSORT checklist​ ​10​ below. Material taken directly 
from the paper (or trial registry) is in ​italics. ​Our additional comments are in ​bold​.  
Title and abstract 
1a Identification as a randomised trial in the title 
Hydroxychloroquine in patients with COVID-19: an ​open-label, randomized, controlled trial 
1b Structured summary of trial design, methods, results, and conclusions. 
Title: Identification of the study as randomised Yes 
Authors: Contact details for the corresponding author Yes 
Trial design: Description of the trial design (eg, parallel, cluster, non-inferiority) Yes 
Methods  
Participants: Eligibility criteria for participants and the settings where the data were collected No 
Interventions: Interventions intended for each group Yes 
Objective: Specific objective or hypothesis Yes 
Outcome: Clearly defined primary outcome for this report Yes 
Randomisation: How participants were allocated to interventions No 
Blinding (masking): Whether or not participants, care givers, and those assessing the outcomes were 
blinded to group assignment 
No 
Results  
Numbers randomised: Number of participants randomised to each group Yes 
Recruitment: Trial status No 
Numbers analysed: Number of participants analysed in each group No 
Outcome: For the primary outcome, a result for each group and the estimated effect size and its precision Yes 
Harms: Important adverse events or side-effects Yes 
Conclusions: General interpretation of the results Yes 
Trial registration: Registration number and name of trial register Yes 
Funding: Source of funding No 
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Introduction 
Background and objectives 
2a Scientific background and explanation of rationale 
See introduction. 
2b Specific objectives or hypotheses 
To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard-of-care (SOC) 
compared with SOC alone in adult patients with COVID-19.​ [​abstract​] 
 
Having encountered numerous challenges, we conducted a multicenter, open-label, 
randomized, controlled trial to assess the efficacy and safety of HCQ sulfate in adult patients 
with COVID-19. ​[​introduction​] 
 
Evaluate the efficacy and safety of high dose Hydroxychloroquine Sulfate Tablets in treatment 
of mild/normal/severe type novel coronavirus pneumonia. ​[​registry​] 
 
 
Methods 
Trial design 
3a Description of trial design (such as parallel, factorial) including allocation ratio 
Having encountered numerous challenges, we conducted a ​multicenter, open-label, andomized, 
controlled trial​ to assess the efficacy and safety of HCQ sulfate in adult patients with COVID-19. 
[​introduction​] 
 
Multicenter, open-label, randomized controlled trial. ​[​abstract​] 
 
This study was a multicenter, randomized, parallel, open-label, trial of oral HCQ in hospitalized 
patients with COVID-19 ​[​methods​] 
 
1:1 allocation ratio implied by​: ​150 patients hospitalized with COVID-19. 75 patients were 
assigned to HCQ plus SOC and 75 were assigned to SOC alone (control group). ​[​abstract​] 
3b Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons 
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No apparent changes.  
 
All authors vouch for the veracity of the data, analyses, and trial protocol and vouch that the trial 
was conducted and reported consistently with the protocol, which together with the statistical 
analysis plan, is available in the appendix.  
Participants 
4a Eligibility criteria for participants 
Eligible patients were at least 18 years of age, had ongoing SARS-CoV-2 infection confirmed 
with real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR). Patients who were 
willing to participate in this trial had to consent not to be enrolled by other clinical trials during 
the study period. A chest computed tomography examination result is needed for determining 
disease severity before randomization. Patients had to receive HCQ orally. Patients with known 
allergy to HCQ or existing conditions that could lead to severe adverse events during the trial 
period were excluded, particularly those with severe liver or renal diseases that could impair the 
ability to metabolize high doses of HCQ. Those unable to co-operate with investigators due to 
cognitive impairments or poor mental status were considered inappropriate for this trial. Female 
patients who were pregnant or during lactation period were excluded. Full eligibility criteria are 
provided in the protocol (appendix). ​[​paper​] 
 
 
Inclusion criteria1. Aged 18 years old and above; 2. Meet the novel coronavirus pneumonia 
(COVID-19) diagnostic criteria. The upper and lower respiratory tract RT-PCR confirmed that 
2019-nCoV nucleic acid positive, chest CT imaging examination could be used in conjunction; 3. 
SaO2/SpO2≤94% under indoor air, or PaO2/FiO2<300mgHg (for severe type patients); 4. Sign 
informed consent; 5. Do not participate in the clinical study of other study drugs within 28 days. 
Exclusion criteria：1. Aged less than 18 years old; 2. Other serious medical diseases such as 
malignant tumor, heart, liver and kidney disease, uncontrollable metabolic disease, etc; 3. Not 
suitable for gastrointestinal administration; 4. Pregnant or lactating women; 5. Those who are 
allergic to the ingredients of this product; 6. Mental state can not cooperate with the observer or 
cognitive impairment; 7. Severe liver disease (such as child Pugh score >=C, AST > 5 times 
ULN); 8. Patients with known severe renal impairment (creatinine clearance rate <=30 ml/min) 
or continuous renal replacement therapy, hemodialysis, peritoneal dialysis.​ [​registry​] 
 
4b Settings and locations where the data were collected 
Patients were enrolled at 16 government-designated COVID-19 treatment centers from three 
provinces in China (Hubei, Henan and Anhui province) between February 11, 2020 and 
February 29, 2020.  
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19 locations listed in the registry.  
Interventions 
5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
Treatment group: standard treatment according to the guideline recommendation combined 
with: Day 1 to day 3: oral hydroxychloroquine sulfate tablets (100mg / tablet, 200mg / tablet), 
400mg each time, 3 times a day; Day 4 to day 14/21: oral hydroxychloroquine sulfate tablets 
(100mg / tablet, 200mg / tablet), 400mg each time, 2 times a day. Control group: standard 
treatment according to the guideline recommendation. Treatment period: 14 days for 
mild/normal type, 21 days for severe type. ​[​registry​] 
 
The patients were treated with SOC aligning with the indications from the updating National 
clinical practice guidelines for COVID-19 in China. Treatment of HCQ was begun within 24 
hours after randomization and was administrated with a loading dose of 1, 200 mg daily for 
three days followed by a maintained dose of 800 mg daily for remaining days (total treatment 
duration: 2 weeks or 3 weeks for mild/moderate or severe patients, respectively). Dose for HCQ 
will be adjusted when adverse events are related to HCQ as judged by investigators.  
6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
 
The primary endpoint for this trial was the negative conversion of SARS-CoV-2 within 28-day.  
 
Key secondary endpoints included the alleviation of clinical symptoms, laboratory parameters, 
and chest radiology within 28-day. Definition for the alleviation of clinical symptoms was 1) 
resolving from fever to an axillary temperature of ≤36.6 and; 2) normalization of SpO2 (>94% on 
room air) and; 3) disappearance of respiratory symptoms including nasal congestion, cough, 
sore throat, sputum production and shortness of breath. Normalization of laboratory parameters 
were focused on CRP, ESR, IL-6 and TNF-α level.  
 
Other secondary outcomes for severe cases included all-cause mortality, clinical status as 
assessed with the six-category ordinal scale on days 7, 14, 21 and 28, days of mechanical 
ventilation, extracorporeal membrane oxygenation, supplemental oxygenation, and hospital stay 
for severe cases. Disease progression was assessed in mild/moderate cases.  
 
Safety outcomes included adverse events that occurred during the study period. Adverse events 
will be coded using the latest version of Medical Dictionary for Regulatory Activities coding 
dictionary and will be recorded in standard medical terminology and graded according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events. 
11 
DOI:10.5281/zenodo.3767943 
6b Any changes to trial outcomes after the trial commenced, with reasons 
Sample size 
7a How sample size was determined 
The trial was designed to enroll approximately 360 subjects (180 per group) to assure a power 
of 80% and the family-wise type-I error ≤0.05. The sample size was calculated based on the 
alternative hypothesis of a 30% increase in the speed of virus nucleic acid negativity, therefore, 
a total of 248 events is needed with a Log-Rank test.  
7b When applicable, explanation of any interim analyses and stopping guidelines 
An interim analysis was planned when around 150 patients were treated for at least 7 days. 
O’Brien-Fleming cumulative α-spending function by Lan-DeMets algorithm（Lan-Demets, 1983)  
was applied to control family-wise type-I error. 
Randomisation 
Sequence generation 
8a Method used to generate the random allocation sequence 
8b Type of randomisation; details of any restriction (such as blocking and block size) 
Patients meeting eligibility criteria were ​stratified according to the disease severity 
(mild/moderate or severe) and were then randomly assigned (in a 1:1 ratio) to receive either 
SOC or SOC plus HCQ. Patients were enrolled by the site investigator. ​The statistician 
performed the randomization 
Allocation concealment mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
...equal numbers of cards with each group assignment number randomly generated by 
computer were placed in sequentially numbered envelopes that were opened as the patients 
were enrolled.  
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Implementation 
10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
No additional information. 
Blinding 
11a If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
No placebo was used and drugs were not masked. 
 
Neither patients, nor investigators, nor statisticians were masked to treatment assignment. 
11b If relevant, description of the similarity of interventions 
Statistical methods 
12a Statistical methods used to compare groups for primary and secondary outcomes 
The overall negative conversion rate was estimated and compared by analyzing time to virus 
nucleic acid negativity using the Kaplan-Meier method on intention-to-treat population. The 
hazard ratio was estimated by the Cox model, which is the higher, the more rapid the 
conversion is. The same approach was applied to analyze other key secondary endpoints. 
Forest plot was used to display hazard ratios generated for each subgroup.  
 
Absolute changes from baseline of CRP and blood lymphocyte count by last assessment were 
compared between actual treatment groups using the Two-Sample T-test. Significance was 
claimed for other analyses than primary analysis if p-value <0.05.  
 
Data analyses were conducted on SAS version 9.4. 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 
Results 
Participant flow (a diagram is strongly recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
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13b For each group, losses and exclusions after randomisation, together with reasons 
A total of 191 patients admitted with COVID-19 from February 11, 2020 to February, 29 2020, 
were assessed for eligibility, of which 41 did not meet eligibility criteria. The remaining 150 
patients underwent randomization; Among them, 75 patients were assigned to SOC and 75 
patients to SOC plus HCQ group (Figure 1).  
Recruitment 
14a Dates defining the periods of recruitment and follow-up 
2020-02-06To ​2020-06-30​; ​Recruitment status: Completed ​ [​registry​] 
 
14b Why the trial ended or was stopped 
Baseline data 
15 A table showing baseline demographic and clinical characteristics for each group 
The mean age of the patients was 46 years and 55% were male. The mean day from disease 
onset to randomization was 16.6 and 89% of the patients had concomitant medication before 
randomization. The majority of the patients had mild to moderate COVID-19 (99%) and only 2 
patients (1%) were severe upon screening. Baseline demographic, epidemiological and clinical 
characteristics of the patients between the two groups are shown in Table 1. By 14 March 2020 
(the cutoff date for data analysis) The median duration of follow-up was 21 days (range, 2 to 33) 
in the SOC group and 20 days (range, 3 to 31) in the SOC plus HCQ group. Of the 75 patients 
assigned to receive SOC plus HCQ, 6 patients did not receive any dose of HCQ; of them, 3 
patients withdrew consent and 3 patients refuse to be administrated HCQ. 
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Numbers analysed 
16 For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
Outcomes and estimation 
17a For each primary and secondary outcome, results for each group, and the 
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estimated effect size and its precision (such as 95% confidence interval) 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
Primary: 
Overall, the negative conversion rate of SARS-CoV-2 among patients who were assigned to 
receive SOC plus HCQ was 85.4% (95% confidence interval [CI], 73.8%, 93.8%), similar to that 
of the SOC group 81.3% (95%CI, 71.2% to 89.6%) within 28-day.  
 
Negative conversion rate at specific time-point, 4-, 7-, 10-, 14- or 21-day was also similar 
between the two groups.  
 
The negative conversion time did not differ between SOC plus HCQ and SOC group (median, 8 
days vs. 7 days; hazard ratio, 0.846; 95%CI, 0.580 to 1.234; P=0.341) (Figure 2_panel A).  
 
Secondary: 
The overall rate of symptoms alleviation within 28-day was not different between patients with 
SOC with (59.9%, 95%CI, 45.0% to 75.3%) and without HCQ (66.6%, 95%CI, 39.5% to 90.9%).  
 
The median time to alleviation of clinical symptoms was similar in the SOC plus HCQ group than 
that in the SOC group (19 days versus 21 days).  
 
More rapid alleviation of clinical symptoms with SOC plus HCQ than with SOC alone was 
observed during the second week since randomization (Figure 3_panel A).  
 
Comparing to SOC alone, the addition of HCQ on SOC led to more rapid normalization of 
elevated baseline CRP and recovery of baseline lymphocytopenia, although the overall 
improvement rate become similar within the 28-day (Figure 4_panel A, B).  
 
The declined value of CRP from baseline by last assessment was significantly greater in SOC 
plus HCQ group than in the SOC group (absolute change, 6.986 versus 2.723 milligram/liter, 
P=0.045) (Figure 5).  
 
Similarly, the elevation of blood lymphocyte count at last assessment from baseline was greater 
in SOC plus HCQ group than that in the SOC group (absolute change, 0.062 versus 0.008 
×109/liter, P=0.547) (Figure 5).  
 
Comprehensive analysis for other prespecified secondary outcomes including the reduction of 
erythrocyte sedimentation rate, IL-6 or TNF-α was not available due to very limited data of these 
parameters on pre-specified visiting date.  
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Ancillary analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
 
Post hoc analyses were performed in subgroups to explore any decrease of negative 
conversion time by the addition of HCQ upon SOC. No such effects were observed in the 
analyzed subgroups according to age (≥45 years versus <45 years), BMI value (≥24 kg/m2 
versus <24 kg/m2), presence or absence of existing conditions, days between disease onset 
and randomization (≥7 days versus <7 days), baseline CRP value (≥upper limit of normal versus 
<upper limit of normal), baseline lymphocyte count (<lower limit of normal versus ≥lower limit of 
normal) and with or without contaminant use of potential anti-viral agents for treating COVID-19 
during the study period (Figure 2_panel B).  
 
The efficacy of HCQ on the alleviation of symptoms (Hazard ratio, 8.83, 95%CI, 1.09 to 71.3) 
was more evident when the confounding effects of other anti-viral agents were removed in the 
post-hoc subgroup analysis (Figure 3_panel B). No significant difference between SOC plus 
HCQ group and SOC group on symptoms improvement was observed in other subgroup 
analyses (Figure 3_panel B) 
 
 
Harms 
19 All important harms or unintended effects in each group (for specific guidance see 
CONSORT for harms42) 
 
Six patients assigned to the SOC plus HCQ group but did not receive HCQ treatment were 
classified as HCQ non-recipient in the safety population. One patient in the SOC group wrongly 
received 14-day of HCQ treatment with an accumulative dose of 11, 600 mg. This patient was 
classified as HCQ recipient in the safety population (Figure 1). Safety endpoints were compared 
between HCQ recipient and non-recipient (Table 2). In HCQ recipients, the median duration of 
HCQ treatment was 14 days (range, 1 to 22). Between randomization and final visit, a total of 21 
patients (30%) in the SOC plus HCQ group reported adverse events, significantly (P=0.001) 
higher than those (7 patients, 8.8%) reported in the SOC group (Table 2). No patients reported 
serious adverse events in the SOC group whereas 2 patients reported serious adverse events 
due to disease progression and upper respiratory infection. The case with upper respiratory 
infection had finished the 14-day treatment of HCQ and developed throat-drying and 
pharyngalgia without evidence of pneumonia on chest computed tomography during the 
extended follow-up period. The most common adverse events in the SOC plus HCQ group were 
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diarrhea, which was more frequent than that in the SOC group (10% versus 0%, P=0.004). HCQ 
was discontinued in one patient due to blurred vision and was adjusted to give a lower dose in 
one patient who reported thirst. These two adverse events were both transient with a period of 
1-2 day  
Discussion 
Limitations 
20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
Generalisability 
21 Generalisability (external validity, applicability) of the trial findings 
Interpretation 
22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
Other information 
Registration 
23 Registration number and name of trial registry 
ChiCTR2000029868 
http://www.chictr.org.cn/showprojen.aspx?proj=49524 
 
Protocol 
24 Where the full trial protocol can be accessed, if available 
The pre-print says there is a protocol, but we have not been able to find it.  
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25 Sources of funding and other support (such as supply of drugs), role of funders 
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